Sonova Competitors

Sonova (OTCMKTS:SONVY) and Varian Medical Systems (NYSE:VAR) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. Comparatively, 87.0% of Varian Medical Systems shares are owned by institutional investors. 0.8% of Varian Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Sonova has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sonova and Varian Medical Systems, as provided by MarketBeat.com.

Varian Medical Systems has a consensus price target of $148.2778, suggesting a potential downside of 15.65%. Given Varian Medical Systems' higher possible upside, analysts plainly believe Varian Medical Systems is more favorable than Sonova.

Earnings and Valuation

This table compares Sonova and Varian Medical Systems' top-line revenue, earnings per share and valuation.

Sonova has higher earnings, but lower revenue than Varian Medical Systems. Sonova is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sonova and Varian Medical Systems' net margins, return on equity and return on assets.

Summary

Varian Medical Systems beats Sonova on 10 of the 14 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and Masimo (NASDAQ:MASI) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Sonova and Masimo's top-line revenue, earnings per share and valuation.

Sonova has higher revenue and earnings than Masimo. Sonova is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Sonova and Masimo, as provided by MarketBeat.

Masimo has a consensus price target of $262.8333, suggesting a potential upside of 5.59%. Given Masimo's stronger consensus rating and higher possible upside, analysts clearly believe Masimo is more favorable than Sonova.

Risk & Volatility

Sonova has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Insider and Institutional Ownership

1.1% of Sonova shares are held by institutional investors. Comparatively, 81.6% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sonova and Masimo's net margins, return on equity and return on assets.

Summary

Masimo beats Sonova on 12 of the 14 factors compared between the two stocks.

Getinge (OTCMKTS:GNGBY) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Getinge and Sonova, as provided by MarketBeat.com.

Profitability

This table compares Getinge and Sonova's net margins, return on equity and return on assets.

Insider and Institutional Ownership

0.0% of Getinge shares are held by institutional investors. Comparatively, 1.1% of Sonova shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Getinge has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Earnings and Valuation

This table compares Getinge and Sonova's gross revenue, earnings per share and valuation.

Sonova has higher revenue and earnings than Getinge.

Summary

Sonova beats Getinge on 7 of the 11 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Risk & Volatility

Sonova has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Sonova and LivaNova, as reported by MarketBeat.com.

LivaNova has a consensus price target of $66.7143, suggesting a potential downside of 9.82%. Given LivaNova's stronger consensus rating and higher probable upside, analysts clearly believe LivaNova is more favorable than Sonova.

Profitability

This table compares Sonova and LivaNova's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Sonova and LivaNova's gross revenue, earnings per share and valuation.

Sonova has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Sonova, indicating that it is currently the more affordable of the two stocks.

Summary

LivaNova beats Sonova on 9 of the 14 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and CONMED (NYSE:CNMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

Sonova has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Insider and Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sonova and CONMED, as reported by MarketBeat.

CONMED has a consensus price target of $104.60, suggesting a potential downside of 18.20%. Given CONMED's stronger consensus rating and higher probable upside, analysts clearly believe CONMED is more favorable than Sonova.

Profitability

This table compares Sonova and CONMED's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Sonova and CONMED's revenue, earnings per share (EPS) and valuation.

Sonova has higher revenue and earnings than CONMED. Sonova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats Sonova on 9 of the 14 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and InMode (NASDAQ:INMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Profitability

This table compares Sonova and InMode's net margins, return on equity and return on assets.

Risk and Volatility

Sonova has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sonova and InMode, as reported by MarketBeat.

InMode has a consensus price target of $71.50, suggesting a potential upside of 0.48%. Given InMode's stronger consensus rating and higher probable upside, analysts clearly believe InMode is more favorable than Sonova.

Insider and Institutional Ownership

1.1% of Sonova shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sonova and InMode's revenue, earnings per share (EPS) and valuation.

Sonova has higher revenue and earnings than InMode. Sonova is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats Sonova on 11 of the 13 factors compared between the two stocks.